En Route to New Therapeutic Options for Iron Overload Diseases: Matriptase-2 as a Target for Kunitz-Type Inhibitors

Chembiochem. 2016 Apr 1;17(7):595-604. doi: 10.1002/cbic.201500651. Epub 2016 Feb 16.

Abstract

The cell-surface serine protease matriptase-2 is a critical stimulator of iron absorption by negatively regulating hepcidin, the key hormone of iron homeostasis. Thus, it has attracted much attention as a target in primary and secondary iron overload diseases. Here, we have characterised Kunitz-type inhibitors hepatocyte growth factor activator inhibitor 1 (HAI-1) and HAI-2 as powerful, slow-binding matriptase-2 inhibitors. The binding modes of the matriptase-2-HAI complexes were suggested by molecular modelling. Different assays, including cell-free and cell-based measurements of matriptase-2 activity, determination of inhibition constants and evaluation of matriptase-2 inhibition by analysis of downstream effects in human liver cells, demonstrated that matriptase-2 is an excellent target for Kunitz inhibitors. In particular, HAI-2 is considered a promising scaffold for the design of potent and selective matriptase-2 inhibitors.

Keywords: enzymes; inhibitors; iron homeostasis; matriptase-2; membrane proteins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Down-Regulation
  • Drug Delivery Systems*
  • Enzyme Activation
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Iron Overload / drug therapy*
  • Iron Overload / enzymology
  • Liver / enzymology
  • Membrane Proteins / antagonists & inhibitors*
  • Membrane Proteins / genetics
  • Models, Molecular
  • Protein Domains / genetics
  • Proteinase Inhibitory Proteins, Secretory / antagonists & inhibitors
  • Proteinase Inhibitory Proteins, Secretory / chemistry
  • Serine Endopeptidases / genetics

Substances

  • Enzyme Inhibitors
  • Membrane Proteins
  • Proteinase Inhibitory Proteins, Secretory
  • SPINT1 protein, human
  • Serine Endopeptidases
  • matriptase 2